SCHEMBL2905339

SCHEMBL2905339

CN1CCN(Cc2cn(-c3ccc(-c4ccccc4)cc3)nc2-c2ccccc2F)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.53
NPC1 O15118 1/20 0.49
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
POLB P06746 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
LMNA P02545 2/20 0.47
ATM Q13315 1/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
GAA P10253 2/20 0.44
KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907387 0.93 ALDH1A1 (0.56) ALDH1A1NPC1KDM4EMEN1KMT2A
SCHEMBL2908931 0.87 ALDH1A1 (0.49) ALDH1A1NPC1KDM4EMEN1KMT2A
SCHEMBL2908465 0.84 ALDH1A1 (0.53) ALDH1A1NPC1KDM4EMEN1KMT2A
SCHEMBL2909895 0.82 DRD2 (0.56) ALDH1A1NPC1KDM4EMEN1KMT2A
SCHEMBL2906130 0.80 CYP2A13 (0.53) ALDH1A1NPC1KDM4EMEN1KMT2A
SCHEMBL18965049 0.77 ALDH1A1 (0.52) ALDH1A1NPC1KDM4EMEN1KMT2A
SCHEMBL1689504 0.76 SMO (0.45) ALDH1A1L3MBTL1DRD2DRD4DRD3
SCHEMBL2902533 0.74 KMT2A (0.52) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL10080804 0.74 KCNH2 (0.46) ALDH1A1DRD2DRD4DRD3
SCHEMBL7261049 0.73 CHKA (0.50) ALDH1A1KDM4EPOLBDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885NPC1 1748/4885KDM4E 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.